UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report findsBusiness live – latest updatesThe pipeline of new drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050.The number of projects from large pharma companies has shrunk by 35% over the past five years, from 92 to 60 medicines...